| Year |
Citation |
Score |
| 2019 |
Chakravarthy AB, Zhao F, Meropol NJ, Flynn PJ, Wagner LI, Sloan J, Diasio RB, Mitchell EP, Catalano P, Giantonio BJ, Catalano RB, Haller DG, Awan RA, Mulcahy MF, O'Brien TE, et al. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204). The Oncologist. PMID 31852811 DOI: 10.1634/Theoncologist.2019-0437 |
0.305 |
|
| 2019 |
Etienne-Grimaldi M, Cozic N, Boyer J, Boige V, Diasio R, Taieb J, Meulendijks D, Palles C, Zanger U, Deenen M, Largiader C, Boisdron-Celle M, Marinaki A, Jennings B, Gross E, et al. FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity Annals of Oncology. 30: v214. DOI: 10.1093/Annonc/Mdz246.046 |
0.328 |
|
| 2018 |
Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Won Kim T, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Therapeutic Drug Monitoring in Oncology: IATDMCT Recommendations for 5-Fluorouracil Therapy. Clinical Pharmacology and Therapeutics. PMID 29923599 DOI: 10.1002/Cpt.1124 |
0.311 |
|
| 2018 |
Siddiqui NS, Purvey S, Hamal R, Zhang L, Diasio RB, Saif WM. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among pts with 5-FU/capecitabine (CAP)-related adverse events (AEs): Experience of 2 decades. Journal of Clinical Oncology. 36: 2576-2576. DOI: 10.1200/Jco.2018.36.15_Suppl.2576 |
0.333 |
|
| 2018 |
Wu R, Nie Q, Kubica PA, Wang Z, Shrestha S, Trogstad-Isaacson CS, Jerde CR, Tapper EE, Bouchonville KJ, Offer SM, Diasio RB. Abstract 911: Targeting the mutant KRAS/BRAF-induced enhancer as an approach to overcome resistance to 5-fluorouracil-based chemotherapy in colorectal cancer Cancer Research. 78: 911-911. DOI: 10.1158/1538-7445.Am2018-911 |
0.364 |
|
| 2018 |
Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Offer SM, Diasio RB. Abstract 3893: Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity Cancer Research. 78: 3893-3893. DOI: 10.1158/1538-7445.Am2018-3893 |
0.367 |
|
| 2017 |
Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, ... ... Diasio RB, et al. Future cancer research priorities in the USA: a Lancet Oncology Commission. The Lancet. Oncology. 18: e653-e706. PMID 29208398 DOI: 10.1016/S1470-2045(17)30698-8 |
0.307 |
|
| 2017 |
Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB. Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clinical Pharmacology and Therapeutics. PMID 28295243 DOI: 10.1002/Cpt.685 |
0.316 |
|
| 2017 |
Flores JP, Diasio RB, Saif MW. Drug metabolism and pancreatic cancer. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology. 30: 54-61. PMID 28042238 DOI: 10.20524/Aog.2016.0074 |
0.345 |
|
| 2016 |
Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB. Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clinical Pharmacology and Therapeutics. PMID 27727460 DOI: 10.1002/Cpt.531 |
0.351 |
|
| 2016 |
Saif MW, Smith MH, Maloney A, Diasio RB. Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor. Annals of Gastroenterology : Quarterly Publication of the Hellenic Society of Gastroenterology. 29: 551-556. PMID 27708529 DOI: 10.20524/Aog.2016.0053 |
0.365 |
|
| 2016 |
Wu R, Nie Q, Tapper EE, Jerde CR, Dunlap GS, Shrestha S, Elraiyah TA, Offer SM, Diasio RB. Histone H3K27 trimethylation modulates 5-fluorouracil resistance by inhibiting PU.1 binding to the DPYD promoter. Cancer Research. PMID 27578004 DOI: 10.1158/0008-5472.Can-16-1306 |
0.343 |
|
| 2016 |
Saif MW, Diasio RB. Benefit of uridine triacetate (Vistogard) in rescuing severe 5-fluorouracil toxicity in patients with dihydropyrimidine dehydrogenase (DPYD) deficiency. Cancer Chemotherapy and Pharmacology. PMID 27278667 DOI: 10.1007/S00280-016-3063-1 |
0.367 |
|
| 2016 |
Saif MW, Wasif K, Butler-Bowen H, Miller K, Diasio RB. Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient. Therapeutic Advances in Gastroenterology. 9: 121-7. PMID 26770273 DOI: 10.1177/1756283X15604115 |
0.326 |
|
| 2016 |
Offer SM, Diasio RB. Is It Finally Time for a Personalized Medicine Approach for Fluorouracil-Based Therapies? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 205-7. PMID 26644533 DOI: 10.1200/Jco.2015.64.2546 |
0.339 |
|
| 2016 |
Wu R, Offer S, Jerde C, Dunlap G, Diasio R. Abstract B49: Histone H3K27 tri-methylation regulates DPYD expression and cellular sensitivity of 5-fluorouracil Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-B49 |
0.323 |
|
| 2016 |
Shrestha S, Offer SM, Diasio RB. Abstract LB-195: The intronic DPYD variant rs75017182 correlates with a modest reduction in DPD enzyme activity Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-195 |
0.369 |
|
| 2015 |
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Grothey A, Polite B, Chan E, Gill S, Kahlenberg MS, Nair SG, Shields AF, Goldberg RM, Diasio RB. Association between DPYD c.1129-5923 C>G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance). Pharmacogenetics and Genomics. PMID 26658227 DOI: 10.1097/Fpc.0000000000000197 |
0.362 |
|
| 2015 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzi?ski M, et al. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications. 6: 7539. PMID 26198393 DOI: 10.1038/Ncomms8539 |
0.329 |
|
| 2015 |
Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. HapB3 and the deep intronic variant c.1129-5923 C>G of the dihydropyrimidine dehydrogenase gene (DPYD) to predict toxicity in stage III colon cancer (CC) patients (pts) (NCCTG Alliance N0147). Journal of Clinical Oncology. 33: 508-508. DOI: 10.1200/Jco.2015.33.3_Suppl.508 |
0.318 |
|
| 2015 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Diasio RB, Wu T, Jenkins RB, Sinicrope FA. Comparison of HER2 gene amplification (AMP) in primary esophageal and gastroesophageal junction adenocarcinomas (EAC) and their metastatic regional lymph nodes (MLNs). Journal of Clinical Oncology. 33: 4059-4059. DOI: 10.1200/Jco.2015.33.15_Suppl.4059 |
0.311 |
|
| 2014 |
Sha D, Lee AM, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3319-27. PMID 24727325 DOI: 10.1158/1078-0432.Ccr-14-0069 |
0.327 |
|
| 2014 |
Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Research. 74: 2545-54. PMID 24648345 DOI: 10.1158/0008-5472.Can-13-2482 |
0.404 |
|
| 2014 |
Lee AM, Diasio RB. Genetic biomarkers for Fluorouracil toxicity prediction: the long road to clinical utility. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 989-90. PMID 24590640 DOI: 10.1200/Jco.2013.53.4479 |
0.402 |
|
| 2014 |
Saif MW, Lee AM, Offer SM, McConnell K, Relias V, Diasio RB. A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. Mayo Clinic Proceedings. 89: 131-6. PMID 24388031 DOI: 10.1016/j.mayocp.2013.09.008 |
0.33 |
|
| 2014 |
Yoon HH, Sukov WR, Shi Q, Sattler CA, Wiktor AE, Diasio RB, Wu TT, Jenkins RB, Sinicrope FA. HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma. Cancer. 120: 415-24. PMID 24151090 DOI: 10.1002/Cncr.28435 |
0.306 |
|
| 2014 |
Offer SM, Diasio RB. Response to "a case of 5-FU-Related severe toxicity associated with the P.Y186C DPYD Variant" Clinical Pharmacology and Therapeutics. 95: 137. PMID 24107927 DOI: 10.1038/Clpt.2013.207 |
0.324 |
|
| 2013 |
Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clinical Pharmacology and Therapeutics. 94: 640-5. PMID 23988873 DOI: 10.1038/Clpt.2013.172 |
0.381 |
|
| 2013 |
Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clinical Pharmacology and Therapeutics. 94: 158-66. PMID 23588312 DOI: 10.1038/Clpt.2013.69 |
0.758 |
|
| 2013 |
Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of enzyme activity. Cancer Research. 73: 1958-68. PMID 23328581 DOI: 10.1158/0008-5472.Can-12-3858 |
0.404 |
|
| 2013 |
Bertino EM, Bekaii-Saab T, Fernandez S, Diasio RB, Karim NA, Otterson GA, Villalona-Calero MA. A phase II study of modulated-capecitabine and docetaxel in chemonaive patients with advanced non-small cell lung cancer (NSCLC). Lung Cancer (Amsterdam, Netherlands). 79: 27-32. PMID 23079156 DOI: 10.1016/J.Lungcan.2012.09.013 |
0.315 |
|
| 2013 |
Lee A, Shi Q, Pavey ES, Sargent DJ, Alberts SR, Sinicrope FA, Berenberg J, Goldberg RM, Diasio RB. Validation of DPYD variants DPYD*2A, I560S, and D949V as predictors of 5-fluorouracil (5-FU)-related toxicity in stage III colon cancer (CC) patients from adjuvant trial NCCTG N0147. Journal of Clinical Oncology. 31: 3510-3510. DOI: 10.1200/Jco.2013.31.15_Suppl.3510 |
0.36 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Lewis MA, Sattler CA, Wiktor AE, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3932-8. PMID 22987085 DOI: 10.1200/Jco.2012.43.1890 |
0.331 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu TT, Diasio RB, Jenkins RB, Sinicrope FA. Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 546-54. PMID 22252257 DOI: 10.1158/1078-0432.Ccr-11-2272 |
0.304 |
|
| 2012 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Wu T, Diasio RB, Jenkins RB, Sinicrope FA. Adverse prognostic impact of heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 30: 4009-4009. DOI: 10.1200/Jco.2012.30.15_Suppl.4009 |
0.342 |
|
| 2012 |
Sloan JA, Shi Q, Lee A, Diasio RB, Pavey ES, Sargent DJ, Goldberg RM, Sinicrope FA, Mahoney MR, Alberts SR. Relationship between genetic markers and quality of life (QOL) in stage III colon cancer (CC) patients (pts) prior to adjuvant treatment (N0147). Journal of Clinical Oncology. 30: 3617-3617. DOI: 10.1200/Jco.2012.30.15_Suppl.3617 |
0.33 |
|
| 2012 |
Sha D, Lee A, Shi Q, Alberts SR, Sargent DJ, Sinicrope FA, Diasio RB. Association study of the let-7 microRNA-binding site polymorphism in 3'-untranslated region (UTR) of the KRAS gene in stage III colon cancers from adjuvant trial NCCTG N0147. Journal of Clinical Oncology. 30: 3564-3564. DOI: 10.1200/Jco.2012.30.15_Suppl.3564 |
0.37 |
|
| 2012 |
Gupta M, Hu G, Offer S, Maurer MJ, Wellik L, Han JJ, Dogan A, Diasio RB, Witzig TE. Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes. Blood. 120: 2655-2655. DOI: 10.1182/Blood.V120.21.2655.2655 |
0.308 |
|
| 2011 |
Yoon HH, Shi Q, Sukov WR, Wiktor AE, Khan M, Sattler CA, Grothey A, Wu T, Diasio RB, Jenkins RB, Sinicrope F. HER2 expression/amplification: Frequency, clinicopathologic features, and prognosis in 713 patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4012. PMID 28020553 DOI: 10.1200/Jco.2011.29.15_Suppl.4012 |
0.328 |
|
| 2011 |
Lee AM, Moertel J, Wang K, Diasio RB. Abstract 5451: High-throughput detection of dihydropyrimidine dehydrogenase gene (DPYD) variants using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) Cancer Research. 71: 5451-5451. DOI: 10.1158/1538-7445.Am2011-5451 |
0.411 |
|
| 2011 |
Offer SM, Wegner NJ, Diasio RB. Abstract 4404: Post-transcriptional regulation of dihydropyrimidine dehydrogenase (DPD) by the microRNAs mir27a and mir27b Cancer Research. 71: 4404-4404. DOI: 10.1158/1538-7445.Am2011-4404 |
0.365 |
|
| 2010 |
Saif MW, Sellers S, Diasio RB, Douillard JY. A phase I dose-escalation study of edotecarin (J-107088) combined with infusional 5-fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anti-Cancer Drugs. 21: 716-23. PMID 20581657 DOI: 10.1097/Cad.0B013E32833Cb658 |
0.33 |
|
| 2010 |
Lee AM, Diasio RB. ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer? Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3319-21. PMID 20570925 DOI: 10.1158/1078-0432.Ccr-10-1059 |
0.324 |
|
| 2009 |
Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R. A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4083. PMID 27961640 DOI: 10.1200/Jco.2009.27.15_Suppl.4083 |
0.309 |
|
| 2009 |
Ezzeldin HH, Acosta EP, Mattison LK, Fourie J, Modak A, Diasio RB. (13)C-5-FU breath test current status and future directions: a comprehensive review. Journal of Breath Research. 3: 047002. PMID 21386199 DOI: 10.1088/1752-7155/3/4/047002 |
0.764 |
|
| 2009 |
Saif MW, Hashmi S, Bell D, Diasio RB. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival. Expert Opinion On Drug Safety. 8: 507-14. PMID 19663627 DOI: 10.1517/14740330903173217 |
0.341 |
|
| 2008 |
Saif MW, Seller S, Diasio RB. Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor? Jop : Journal of the Pancreas. 9: 226-9. PMID 18326935 |
0.303 |
|
| 2008 |
Ezzeldin HH, Diasio RB. Predicting fluorouracil toxicity: can we finally do it? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 2080-2. PMID 18299611 DOI: 10.1200/Jco.2007.15.5481 |
0.461 |
|
| 2008 |
Soong R, Shah N, Salto-Tellez M, Tai BC, Soo RA, Han HC, Ng SS, Tan WL, Zeps N, Joseph D, Diasio RB, Iacopetta B. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 19: 915-9. PMID 18245778 DOI: 10.1093/Annonc/Mdm599 |
0.365 |
|
| 2008 |
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism. Pharmacogenetics and Genomics. 18: 25-35. PMID 18216719 DOI: 10.1097/Fpc.0B013E3282F2F134 |
0.778 |
|
| 2008 |
Lustberg MB, Bekaii-Saab TS, Diasio R, Ezzeldin H, Starrett SL, Otterson GA, Villalona MA. Phase II and pharmacogenetic study of docetaxel (D) and capecitabine (C) in chemonaive non-small cell lung cancer (NSCLC) patients (pts) Journal of Clinical Oncology. 26: 19090-19090. DOI: 10.1200/Jco.2008.26.15_Suppl.19090 |
0.338 |
|
| 2007 |
Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS. Pakistan Journal of Medical Sciences. 23: 832-839. PMID 18846242 DOI: 10.1200/Jco.2006.24.18_Suppl.2056 |
0.784 |
|
| 2007 |
Saif MW, Juneja V, Black G, Thronton J, Johnson MR, Diasio RB. Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation? Supportive Cancer Therapy. 4: 211-8. PMID 18632519 DOI: 10.3816/Sct.2007.N.017 |
0.334 |
|
| 2007 |
Thomas HR, Ezzeldin HH, Guarcello V, Mattison LK, Fridley BL, Diasio RB. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism. Pharmacogenetics and Genomics. 17: 973-87. PMID 18075467 DOI: 10.1097/Fpc.0B013E3282F01788 |
0.777 |
|
| 2007 |
Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB. Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase. Cancer Journal (Sudbury, Mass.). 13: 247-56. PMID 17762760 DOI: 10.1097/Ppo.0B013E31813C12B8 |
0.324 |
|
| 2007 |
Zhang X, Soong R, Wang K, Li L, Davie JR, Guarcello V, Diasio RB. Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 85: 337-46. PMID 17612628 DOI: 10.1139/o07-009 |
0.302 |
|
| 2007 |
O'Dwyer PJ, Eckhardt SG, Haller DG, Tepper J, Ahnen D, Hamilton S, Benson AB, Rothenberg M, Petrelli N, Lenz HJ, Diasio R, DuBois R, Sargent D, Sloan J, Johnson CD, et al. Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 2313-21. PMID 17538178 DOI: 10.1200/Jco.2006.08.6900 |
0.317 |
|
| 2007 |
Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics. 8: 257-65. PMID 17324113 DOI: 10.2217/14622416.8.3.257 |
0.442 |
|
| 2007 |
Saif MW, Ezzeldin H, Vance K, Sellers S, Diasio RB. DPYD*2A mutation: the most common mutation associated with DPD deficiency. Cancer Chemotherapy and Pharmacology. 60: 503-7. PMID 17165084 DOI: 10.1007/S00280-006-0392-5 |
0.339 |
|
| 2007 |
Hashmi S, Black G, Bell D, Steg A, Johnson M, Diasio RB, Saif MW. Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase (TP) and its correlation with survival Journal of Clinical Oncology. 25: 4606-4606. DOI: 10.1200/Jco.2007.25.18_Suppl.4606 |
0.311 |
|
| 2007 |
Guarcello V, Fourie J, Lawton MJ, Peters WW, Heslin MJ, Diasio RB. Elucidating the mechanisms responsible for the previous failure of phase III clinical trials with eniluracil (EU) and development of a novel scheduling approach to optimize the efficacy of EU/5-fluorouracil (5-FU) combination therapy Journal of Clinical Oncology. 25: 2557-2557. DOI: 10.1200/Jco.2007.25.18_Suppl.2557 |
0.357 |
|
| 2007 |
Fourie J, Mattison LK, Wood TE, Posey JA, Modak A, Diasio RB. The 2-13C-5-fluorouracil breath test (FUBT) as a novel, rapid method for assessment of dihydropyrimidine dehydrogenase (DPD) activity in cancer patients: Initial characterization and comparison to the 2-13C-uracil breath test (UraBT) Journal of Clinical Oncology. 25: 2551-2551. DOI: 10.1200/Jco.2007.25.18_Suppl.2551 |
0.764 |
|
| 2006 |
Saif MW, Elfiky A, Diasio R. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clinical Colorectal Cancer. 6: 219-23. PMID 17026792 DOI: 10.3816/Ccc.2006.N.039 |
0.39 |
|
| 2006 |
Saif MW, Hashmi S, Mattison L, Donovan WB, Diasio RB. Peripheral neuropathy exacerbation associated with topical 5-fluorouracil. Anti-Cancer Drugs. 17: 1095-8. PMID 17001184 DOI: 10.1097/01.Cad.0000231479.30524.0E |
0.744 |
|
| 2006 |
Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 5491-5. PMID 17000684 DOI: 10.1158/1078-0432.Ccr-06-0747 |
0.773 |
|
| 2006 |
Zhang X, Li L, Fourie J, Davie JR, Guarcello V, Diasio RB. The role of Sp1 and Sp3 in the constitutive DPYD gene expression. Biochimica Et Biophysica Acta. 1759: 247-56. PMID 16806531 DOI: 10.1016/J.Bbaexp.2006.05.001 |
0.373 |
|
| 2006 |
Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, Wang W, Gillespie GY, Johnson MR. Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM). Journal of Neuro-Oncology. 80: 261-74. PMID 16773218 DOI: 10.1007/S11060-006-9191-4 |
0.338 |
|
| 2006 |
Saif MW, Black G, Johnson M, Russo S, Diasio R. Radiation recall phenomenon secondary to capecitabine: possible role of thymidine phosphorylase. Cancer Chemotherapy and Pharmacology. 58: 771-5. PMID 16552574 DOI: 10.1007/S00280-006-0223-8 |
0.313 |
|
| 2006 |
Saif MW, Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency? Clinical Colorectal Cancer. 5: 359-62. PMID 16512996 DOI: 10.3816/Ccc.2006.N.007 |
0.412 |
|
| 2006 |
Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, Wang K, Buchsbaum DJ, Vickers SM, Russo S, Diasio RB, Frost AR, LoBuglio AF, Grizzle WE, Johnson MR. Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. The Journal of Molecular Diagnostics : Jmd. 8: 76-83. PMID 16436637 DOI: 10.2353/Jmoldx.2006.040402 |
0.726 |
|
| 2006 |
Mattison LK, Fourie J, Hirao Y, Koga T, Desmond RA, King JR, Shimizu T, Diasio RB. The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 549-55. PMID 16428499 DOI: 10.1158/1078-0432.Ccr-05-2020 |
0.759 |
|
| 2006 |
Saif MW, Mattison L, Carollo T, Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency in an Indian population. Cancer Chemotherapy and Pharmacology. 58: 396-401. PMID 16421754 DOI: 10.1007/S00280-005-0174-5 |
0.725 |
|
| 2006 |
Juneja V, Black G, Thornton J, Russo S, Johnson M, Diasio R, Saif MW. Hand-foot syndrome (HFS) in patients treated with capecitabine (CAP) and the role of thymidine phosphorylase (TP) and dihydropyrimidine dehydrogenase (DPD) Journal of Clinical Oncology. 24: 8615-8615. DOI: 10.1200/Jco.2006.24.18_Suppl.8615 |
0.311 |
|
| 2006 |
Reed HA, Ezzeldin HH, Mattison LK, Diasio RB. Molecular basis of altered uracil catabolism in individuals with 5-FU toxicity and normal DPD enzyme activity Journal of Clinical Oncology. 24: 3070-3070. DOI: 10.1200/Jco.2006.24.18_Suppl.3070 |
0.787 |
|
| 2006 |
Fourie J, Guarcello V, Diasio RB. Dose dependent inhibition of uridine phosphorylase (UP) by eniluracil (EU): Was the clinical inferiority of the EU/5-fluorouracil (5-FU) phase III trials due to an unrecognized inhibition of 5-FU anabolism? Journal of Clinical Oncology. 24: 2058-2058. DOI: 10.1200/Jco.2006.24.18_Suppl.2058 |
0.345 |
|
| 2006 |
Soong RC, Shah N, Salto-Tellez M, Han HC, Ng SS, Zeps N, Joseph D, Diasio RB, Iacopetta BJ. Prognostic and predictive significance of 5-fluorouracil metabolic enzymes in colorectal cancer Journal of Clinical Oncology. 24: 2021-2021. DOI: 10.1200/Jco.2006.24.18_Suppl.2021 |
0.374 |
|
| 2006 |
Roy S, Russo S, Black G, Eloubeidi MA, Steg A, Zelterman D, Johnson MR, Diasio RB, Saif MW. Upregulation of thymidine phosphorylase (TP) by radiation (XRT): Phase II study of capecitabine (CAP) with XRT in pts with locally advanced (LA) pancreatic cancer Journal of Clinical Oncology. 24: 14001-14001. DOI: 10.1200/Jco.2006.24.18_Suppl.14001 |
0.326 |
|
| 2006 |
MATTISON L, ACOSTA E, FOURIE J, DIASIO R. LBOVI-B-2Describing the catabolism of orally administered 2-13C-uracil in normal and dihydropyrimidine dehydrogenase deficient subjects using a parent/metabolite/breath model Clinical Pharmacology & Therapeutics. 79: P83-P83. DOI: 10.1016/J.Clpt.2005.12.298 |
0.748 |
|
| 2005 |
Mattison LK, Fourie J, Carpenter M, Ezzeldin H, Johnson MR, Saif M, Modak A, Diasio RB. Evidence for increased incidence of dihydropyrimidine dehydrogenase (DPD) deficiency in African Americans compared to Caucasians. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2004. PMID 27946814 DOI: 10.1200/Jco.2005.23.16_Suppl.2004 |
0.772 |
|
| 2005 |
Blanquicett C, Saif MW, Buchsbaum DJ, Eloubeidi M, Vickers SM, Chhieng DC, Carpenter MD, Sellers JC, Russo S, Diasio RB, Johnson MR. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8773-81. PMID 16361565 DOI: 10.1158/1078-0432.Ccr-05-0627 |
0.735 |
|
| 2005 |
Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 8699-705. PMID 16361556 DOI: 10.1158/1078-0432.Ccr-05-1520 |
0.776 |
|
| 2005 |
Saif MW, Eloubeidi MA, Russo S, Steg A, Thornton J, Fiveash J, Carpenter M, Blanquicett C, Diasio RB, Johnson MR. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8679-87. PMID 16314628 DOI: 10.1200/Jco.2005.02.0628 |
0.739 |
|
| 2005 |
Soong R, Diasio RB. Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics. 6: 835-47. PMID 16296946 DOI: 10.2217/14622416.6.8.835 |
0.341 |
|
| 2005 |
Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Kiechle M, Diasio R, Gross E. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of caucasian individuals Clinical Cancer Research. 11: 5886-5892. PMID 16115930 DOI: 10.1158/1078-0432.Ccr-04-1784 |
0.405 |
|
| 2005 |
Saif MW, Diasio RB. Edotecarin: a novel topoisomerase I inhibitor. Clinical Colorectal Cancer. 5: 27-36. PMID 15929804 DOI: 10.3816/Ccc.2005.N.014 |
0.338 |
|
| 2005 |
Kindwall-Keller T, Otterson GA, Young D, Neki A, Criswell T, Nuovo G, Soong R, Diasio R, Villalona-Calero MA. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1870-6. PMID 15756012 DOI: 10.1158/1078-0432.Ccr-04-1727 |
0.304 |
|
| 2004 |
Mattison LK, Johnson MR, Saif W, Modak AS, Hirao Y, Koga T, Shimizu T, Diasio RB. Validation of a novel [2-(13)C]-uracil breath test (UraBT) to detect dihydropyrimidine dehydrogenase (DPD) deficiency by LC-MS-MS analysis of [2-(13)C]-uracil (URA) and [2-(13)C]-dihydrouracil (DHU) plasma levels. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 2130. PMID 28016902 DOI: 10.1200/Jco.2004.22.14_Suppl.2130 |
0.761 |
|
| 2004 |
Meropol NJ, Gold PJ, Diasio RB, Chen YM, Godfrey T, Hill T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Correlation of thymidine phosphorylase (TP), thymidylate synthase (TS), and dihydropyrimidine dehydrogenase (DPD) expression in primary and metastatic sites with response to capecitabine plus irinotecan in patients with colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3520. PMID 28016533 DOI: 10.1200/Jco.2004.22.14_Suppl.3520 |
0.392 |
|
| 2004 |
Newman AJ, Fiveash J, Rosenfeld S, Johnson M, Diasio R, Wang W, Cockrell-Donohue A, Nabors LB. A phase I study of capecitabine and concurrent radiotherapy (RT) for patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 1537. PMID 28015410 DOI: 10.1200/Jco.2004.22.14_Suppl.1537 |
0.354 |
|
| 2004 |
Ozer H, Diasio RB. Perspectives in the treatment of colorectal cancer. Seminars in Oncology. 31: 14-8. PMID 15726534 DOI: 10.1053/J.Seminoncol.2004.11.023 |
0.334 |
|
| 2004 |
Saif MW, Wood TE, McGee PJ, Diasio RB. Peripheral neuropathy associated with capecitabine. Anti-Cancer Drugs. 15: 767-71. PMID 15494638 DOI: 10.1097/00001813-200409000-00005 |
0.353 |
|
| 2004 |
Ezzeldin H, Hoffmayer C, Soong R, Johnson MR, Lee A, Heslin M, Diasio R. Simultaneous detection of variable number tandem repeats, single nucleotide polymorphisms, and allelic imbalance in the thymidylate synthase gene enhancer region using denaturing high-performance liquid chromatography. Analytical Biochemistry. 334: 276-83. PMID 15494134 DOI: 10.1016/J.Ab.2004.07.025 |
0.304 |
|
| 2004 |
Ezzeldin H, Diasio R. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clinical Colorectal Cancer. 4: 181-9. PMID 15377401 DOI: 10.3816/Ccc.2004.N.018 |
0.389 |
|
| 2004 |
Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 2652-8. PMID 15102667 DOI: 10.1158/1078-0432.Ccr-03-0374 |
0.777 |
|
| 2003 |
Heslin MJ, Yan J, Weiss H, Shao L, Owens J, Lucas VS, Diasio RB. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 52: 399-404. PMID 12904894 DOI: 10.1007/S00280-003-0681-1 |
0.346 |
|
| 2002 |
Blanquicett C, Gillespie GY, Nabors LB, Miller CR, Bharara S, Buchsbaum DJ, Diasio RB, Johnson MR. Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Molecular Cancer Therapeutics. 1: 1139-45. PMID 12481438 |
0.7 |
|
| 2002 |
Diasio RB. Can eniluracil improve 5-fluorouracil therapy? Clinical Colorectal Cancer. 2: 53. PMID 12453337 DOI: 10.1016/S1533-0028(11)70503-5 |
0.343 |
|
| 2002 |
Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil. Cancer Investigation. 20: 992-5. PMID 12449732 DOI: 10.1081/Cnv-120005915 |
0.377 |
|
| 2002 |
Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 3: 485-92. PMID 12164772 DOI: 10.1517/14622416.3.4.485 |
0.788 |
|
| 2002 |
Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB. A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Analytical Biochemistry. 306: 63-73. PMID 12069415 DOI: 10.1006/Abio.2002.5666 |
0.352 |
|
| 2002 |
Blanquicett C, Johnson MR, Heslin M, Diasio RB. Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic gene expression studies. Analytical Biochemistry. 303: 209-14. PMID 11950223 DOI: 10.1006/Abio.2001.5570 |
0.719 |
|
| 2002 |
Adjei AA, Reid JM, Diasio RB, Sloan JA, Smith DA, Rubin J, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Atherton P, Ames MM, Erlichman C. Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 1683-91. PMID 11896120 DOI: 10.1200/Jco.20.6.1683 |
0.337 |
|
| 2002 |
Mattison LK, Johnson MR, Diasio RB. A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. Pharmacogenetics. 12: 133-44. PMID 11875367 DOI: 10.1097/00008571-200203000-00007 |
0.755 |
|
| 2001 |
Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Advances in Enzyme Regulation. 41: 151-7. PMID 11384742 DOI: 10.1016/S0065-2571(00)00011-X |
0.354 |
|
| 2000 |
Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 61: 199-203. PMID 10971206 DOI: 10.1159/000028401 |
0.381 |
|
| 2000 |
Diasio RB. Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines. Drugs. 119-26. PMID 10711850 DOI: 10.2165/00003495-199958003-00016 |
0.316 |
|
| 1997 |
Johnson MR, Yan J, Shao L, Albin N, Diasio RB. Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. Journal of Chromatography. B, Biomedical Sciences and Applications. 696: 183-91. PMID 9323539 DOI: 10.1016/S0378-4347(97)00253-3 |
0.423 |
|
| 1995 |
Zhang R, Lu Z, Zhang X, Zhao H, Diasio RB, Liu T, Jiang Z, Agrawal S. In vivo stability and disposition of a self-stabilized oligodeoxynucleotide phosphorothioate in rats. Clinical Chemistry. 41: 836-43. PMID 7768001 DOI: 10.1093/Clinchem/41.6.836 |
0.373 |
|
| 1995 |
Diasio RB, Van Kuilenburg AB, Lu Z, Zhang R, Van Lenthe H, Bakker HD, Van Gennip AH. Determination of dihydropyrimidine dehydrogenase (DPD) in fibroblasts of a DPD deficient pediatric patient and family members using a polyclonal antibody to human DPD. Advances in Experimental Medicine and Biology. 370: 7-10. PMID 7661001 DOI: 10.1007/978-1-4615-2584-4_2 |
0.301 |
|
| 1995 |
Agrawal S, Zhang X, Lu Z, Zhao H, Tamburin JM, Van J, Cai H, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Zhang R. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration Biochemical Pharmacology. 50: 571-576. PMID 7646565 DOI: 10.1016/0006-2952(95)00160-2 |
0.376 |
|
| 1995 |
Zhang R, LU Z, Zhao H, Zhang X, Diasio RB, Habus I, Jiang Z, Iyer RP, Yu D, Agrawal S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats Biochemical Pharmacology. 50: 545-556. PMID 7646561 DOI: 10.1016/0006-2952(95)00159-W |
0.398 |
|
| 1995 |
Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clinical Pharmacology and Therapeutics. 58: 512-22. PMID 7586945 DOI: 10.1016/0009-9236(95)90171-X |
0.374 |
|
| 1993 |
Lyss AP, Lilenbaum RC, Harris BE, Diasio RB. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Cancer Investigation. 11: 239-40. PMID 8462026 DOI: 10.3109/07357909309024846 |
0.364 |
|
| 1992 |
Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi JP. Clinical pharmacokinetics of 3'-azido-3'-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3'-amino-3'-deoxythymidine. Clinical Pharmacology and Therapeutics. 51: 668-76. PMID 1611806 DOI: 10.1038/Clpt.1992.79 |
0.306 |
|
| 1991 |
Coustère C, Mentré F, Sommadossi JP, Diasio RB, Steimer JL. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients. Cancer Chemotherapy and Pharmacology. 28: 123-9. PMID 2060083 DOI: 10.1007/Bf00689701 |
0.332 |
|
| 1991 |
Zhang RW, Barnes S, Diasio RB. Disposition and metabolism of 2-fluoro-beta-alanine conjugates of bile acids following secretion into bile. Biochimica Et Biophysica Acta. 1096: 179-86. PMID 1902118 DOI: 10.1016/0925-4439(91)90003-R |
0.316 |
|
| 1991 |
Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 68: 499-501. PMID 1648430 DOI: 10.1002/1097-0142(19910801)68:3<499::Aid-Cncr2820680309>3.0.Co;2-F |
0.416 |
|
| 1989 |
Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clinical Pharmacokinetics. 16: 215-37. PMID 2656050 DOI: 10.2165/00003088-198916040-00002 |
0.331 |
|
| 1988 |
Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. The Journal of Clinical Investigation. 81: 47-51. PMID 3335642 DOI: 10.1172/Jci113308 |
0.396 |
|
| 1987 |
Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. The American Journal of Medicine. 83: 236-42. PMID 3303926 DOI: 10.1016/0002-9343(87)90691-7 |
0.308 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2004 |
Ezzeldin H, Johnson MR, Okamoto Y, Diasio R. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 3021-8. PMID 12912951 |
0.299 |
|
| 2004 |
Saif MW, Eloubeidi M, Thornton J, Johns J, Diasio R, Johnson MR, Moisa CF, Russo S. Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4104. PMID 28014502 DOI: 10.1200/Jco.2004.22.90140.4104 |
0.299 |
|
| 2011 |
Gupta M, Hu G, Wellik L, Offer S, Diasio RB, Dogan A, Witzig TE. Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of Cpg Islands, Blood. 118: 3678-3678. DOI: 10.1182/Blood.V118.21.3678.3678 |
0.298 |
|
| 2010 |
Yoon HH, Khan M, Shi Q, Cassivi SD, Wu TT, Quevedo JF, Burch PA, Sinicrope FA, Diasio RB. The prognostic value of clinical and pathologic factors in esophageal adenocarcinoma: a mayo cohort of 796 patients with extended follow-up after surgical resection. Mayo Clinic Proceedings. 85: 1080-9. PMID 21123634 DOI: 10.4065/Mcp.2010.0421 |
0.297 |
|
| 2018 |
Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, Diasio RB. Gene-specific variant classifier (DPYD-Varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clinical Pharmacology and Therapeutics. PMID 29327356 DOI: 10.1002/Cpt.1020 |
0.297 |
|
| 2003 |
Calero MV, Kindwall-Keller T, Soong R, Diasio R, Nuovo G, Otterson G, Criswell T, Neki A, Rhoades C. P-211 Phase II study of docetaxel in combination with capecitabine in patients with previously treated non-small cell lung cancer (NSCLC) Lung Cancer. 41: S144-S145. DOI: 10.1016/S0169-5002(03)92180-5 |
0.296 |
|
| 2007 |
Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: a paradigm for the management of metastatic colorectal cancer. The Oncologist. 12: 38-50. PMID 17227899 DOI: 10.1634/Theoncologist.12-1-38 |
0.296 |
|
| 2012 |
Lewis M, Yoon HH, Shi Q, Diasio RB, Sinicrope FA. Post-recurrence survival in patients with previously resected esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 30: 4075-4075. DOI: 10.1200/Jco.2012.30.15_Suppl.4075 |
0.295 |
|
| 2013 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Wiktor AE, Wu T, Diasio RB, Jenkins RB, Sinicrope FA. HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods. Journal of Clinical Oncology. 31: 2-2. DOI: 10.1200/Jco.2013.31.4_Suppl.2 |
0.294 |
|
| 2006 |
Shah HR, Ledbetter L, Diasio R, Saif MW. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clinical Colorectal Cancer. 5: 354-8. PMID 16512995 DOI: 10.3816/Ccc.2006.N.006 |
0.294 |
|
| 2015 |
Shrestha S, Offer S, Diasio RB. Abstract 5487: Functional analysis of rare dihydropyrimidine dehydrogenase variants relevant to 5-fluorouracil toxicity Cancer Research. 75: 5487-5487. DOI: 10.1158/1538-7445.Am2015-5487 |
0.294 |
|
| 2002 |
Miller CR, Gustin AN, Buchsbaum DJ, Vickers SM, Manne U, Grizzle WE, Cloud GA, Diasio RB, Johnson MR. Quantitation of cytosine deaminase mRNA by real-time reverse transcription polymerase chain reaction: a sensitive method for assessing 5-fluorocytosine toxicity in vitro. Analytical Biochemistry. 301: 189-99. PMID 11814289 DOI: 10.1006/Abio.2001.5511 |
0.293 |
|
| 2000 |
Shestopal SA, Johnson MR, Diasio RB. Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter. Biochimica Et Biophysica Acta. 1494: 162-9. PMID 11072080 DOI: 10.1016/S0167-4781(00)00213-X |
0.293 |
|
| 1995 |
Zhang R, Diasio RB, Lu Z, Liu T, Jiang Z, Galbraith WM, Agrawal S. Pharmacokinetics and tissue distribution in rats of an oligodeoxynucleotide phosphorothioate (GEM 91) developed as a therapeutic agent for human immunodeficiency virus type-1. Biochemical Pharmacology. 49: 929-39. PMID 7741765 DOI: 10.1016/0006-2952(95)00010-W |
0.293 |
|
| 2010 |
Fakih MG, Fetterly G, Egorin MJ, Muindi JR, Espinoza-Delgado I, Zwiebel JA, Litwin A, Holleran JL, Wang K, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3786-94. PMID 20463088 DOI: 10.1158/1078-0432.Ccr-10-0547 |
0.293 |
|
| 1990 |
Johnson MR, Barnes S, Sweeny DJ, Diasio RB. 2-Fluoro-beta-alanine, a previously unrecognized substrate for bile acid coenzyme A:amino acid:N-acyltransferase from human liver. Biochemical Pharmacology. 40: 1241-6. PMID 2119585 DOI: 10.1016/0006-2952(90)90389-3 |
0.291 |
|
| 2001 |
Takebe N, Zhao SC, Ural AU, Johnson MR, Banerjee D, Diasio RB, Bertino JR. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA confers resistance to 5-fluorouracil in murine hematopoietic progenitor cells and human CD34+-enriched peripheral blood progenitor cells. Cancer Gene Therapy. 8: 966-973. PMID 11781659 DOI: 10.1038/Sj.Cgt.7700393 |
0.29 |
|
| 2000 |
Johnson MR, Wang K, Smith JB, Heslin MJ, Diasio RB. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Analytical Biochemistry. 278: 175-84. PMID 10660460 DOI: 10.1006/Abio.1999.4461 |
0.29 |
|
| 1993 |
Lu ZH, Zhang R, Diasio RB. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties. Biochemical Pharmacology. 46: 945-52. PMID 8373446 DOI: 10.1016/0006-2952(93)90505-Q |
0.289 |
|
| 2015 |
Amstutz U, Offer SM, Sistonen J, Joerger M, Diasio RB, Largiadèr CR. Polymorphisms in MIR27A Associated with Early-Onset Toxicity in Fluoropyrimidine-Based Chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2038-44. PMID 25655103 DOI: 10.1158/1078-0432.Ccr-14-2817 |
0.287 |
|
| 2011 |
Figueroa JD, Garcia-Closas M, Humphreys M, Platte R, Hopper JL, Southey MC, Apicella C, Hammet F, Schmidt MK, Broeks A, Tollenaar RA, Van't Veer LJ, Fasching PA, Beckmann MW, Ekici AB, ... ... Diasio R, et al. Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Human Molecular Genetics. 20: 4693-706. PMID 21852249 DOI: 10.1093/Hmg/Ddr368 |
0.286 |
|
| 1978 |
Diasio RB, Bennett JE, Myers CE. Mode of action of 5-fluorocytosine Biochemical Pharmacology. 27: 703-707. PMID 350227 DOI: 10.1016/0006-2952(78)90507-5 |
0.286 |
|
| 2007 |
Budman DR, Soong R, Calabro A, Tai J, Diasio R. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anti-Cancer Drugs. 17: 921-8. PMID 16940802 DOI: 10.1097/01.Cad.0000224457.36522.60 |
0.285 |
|
| 1997 |
Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. Molecular characterization of the dihydropyrimidine dehydrogenase gene Clinical Biochemistry. 30: 262. DOI: 10.1016/S0009-9120(97)87713-2 |
0.284 |
|
| 2009 |
Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs. 69: 1911-34. PMID 19747008 DOI: 10.2165/11315680-000000000-00000 |
0.283 |
|
| 2013 |
Yoon HH, Shi Q, Sukov WR, Sattler CA, Vaidya R, Wiktor AE, Diasio RB, Wu T, Jenkins RB, Sinicrope FA. HER2 status in primary tumors and metastatic regional lymph nodes in patients with esophageal adenocarcinoma (EAC). Journal of Clinical Oncology. 31: 4071-4071. DOI: 10.1200/Jco.2013.31.15_Suppl.4071 |
0.283 |
|
| 1991 |
Daher GC, Naguib FN, el Kouni MH, Zhang RW, Soong SJ, Diasio RB. Inhibition of fluoropyrimidine catabolism by benzyloxybenzyluracil. Possible relevance to regional chemotherapy. Biochemical Pharmacology. 41: 1887-93. PMID 1828154 DOI: 10.1016/0006-2952(91)90128-R |
0.282 |
|
| 2015 |
Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudziński M, et al. Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. Nature Communications. 6: 10203. PMID 26648255 DOI: 10.1038/Ncomms10203 |
0.281 |
|
| 2013 |
Zhang Y, Kent JW, Lee A, Cerjak D, Ali O, Diasio R, Olivier M, Blangero J, Carless MA, Kissebah AH. Fatty acid binding protein 3 (fabp3) is associated with insulin, lipids and cardiovascular phenotypes of the metabolic syndrome through epigenetic modifications in a Northern European family population. Bmc Medical Genomics. 6: 9. PMID 23510163 DOI: 10.1186/1755-8794-6-9 |
0.279 |
|
| 2015 |
Jang JS, Lee A, Li J, Liyanage H, Yang Y, Guo L, Asmann YW, Li PW, Erickson-Johnson M, Sakai Y, Sun Z, Jeon HS, Hwang H, Bungum AO, Edell ES, ... ... Diasio RB, et al. Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers. Scientific Reports. 5: 9755. PMID 25985019 DOI: 10.1038/Srep09755 |
0.278 |
|
| 2010 |
Antoniou AC, Wang X, Fredericksen ZS, McGuffog L, Tarrell R, Sinilnikova OM, Healey S, Morrison J, Kartsonaki C, Lesnick T, Ghoussaini M, Barrowdale D, Peock S, Cook M, ... ... Diasio RB, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nature Genetics. 42: 885-92. PMID 20852631 DOI: 10.1038/Ng.669 |
0.278 |
|
| 2016 |
Nardi EA, Wolfson JA, Rosen ST, Diasio RB, Gerson SL, Parker BA, Alvarnas JC, Levine HA, Fong Y, Weisenburger DD, Fitzgerald CL, Egan M, Stranford S, Carlson RW, Benz EJ. Value, Access, and Cost of Cancer Care Delivery at Academic Cancer Centers. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 837-47. PMID 27407124 DOI: 10.6004/Jnccn.2016.0088 |
0.277 |
|
| 2012 |
Stevens KN, Lindstrom S, Scott CG, Thompson D, Sellers TA, Wang X, Wang A, Atkinson E, Rider DN, Eckel-Passow JE, Varghese JS, Audley T, Brown J, Leyland J, Luben RN, ... ... Diasio RB, et al. Identification of a novel percent mammographic density locus at 12q24. Human Molecular Genetics. 21: 3299-305. PMID 22532574 DOI: 10.1093/Hmg/Dds158 |
0.277 |
|
| 1995 |
Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB. Pharmacokinetics of an anti—human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects Clinical Pharmacology & Therapeutics. 58: 44-53. PMID 7628182 DOI: 10.1016/0009-9236(95)90071-3 |
0.277 |
|
| 1993 |
Sparano JA, Wadler S, Diasio RB, Zhang R, Lu Z, Schwartz EL, Einzig A, Wiernik PH. Phase I trial of low-dose, prolonged continuous infusion fluorouracil plus interferon-alfa: evidence for enhanced fluorouracil toxicity without pharmacokinetic perturbation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1609-17. PMID 8336197 DOI: 10.1200/Jco.1993.11.8.1609 |
0.276 |
|
| 2007 |
Saif MW, Fekrazad MH, Ledbetter L, Diasio RB. Hypokalemia secondary to capecitabine: a hidden toxicity? Therapeutics and Clinical Risk Management. 3: 177-80. PMID 18360625 DOI: 10.2147/Tcrm.2007.3.1.177 |
0.276 |
|
| 2000 |
Chen L, Smith L, Johnson MR, Wang K, Diasio RB, Smith JB. Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells. The Journal of Biological Chemistry. 275: 32227-33. PMID 10918054 DOI: 10.1074/Jbc.M002645200 |
0.275 |
|
| 1991 |
Daher GC, Harris BE, Diasio RB. Metabolism of pyrimidine analogues and their nucleosides. Pharmacology & Therapeutics. 48: 189-222. PMID 2293239 DOI: 10.1016/0163-7258(90)90080-L |
0.275 |
|
| 2018 |
Li Q, Zhang P, Wang Y, Liu D, Luo L, Diasio RB, Yang P, Jiang G. T4 extension alone is more predictive of better survival than a tumour size >7 cm for resected T4N0-1M0 non-small-cell lung cancer. European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association For Cardio-Thoracic Surgery. PMID 30508081 DOI: 10.1093/Ejcts/Ezy360 |
0.274 |
|
| 2011 |
Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, ... ... Diasio RB, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature Genetics. 43: 1210-4. PMID 22037553 DOI: 10.1038/Ng.985 |
0.273 |
|
| 2006 |
Diasio RB, Fourie J. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art. Drugs. 66: 1441-63. PMID 16906777 DOI: 10.2165/00003495-200666110-00003 |
0.273 |
|
| 2022 |
Diasio RB, Offer SM. Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy. Cancers. 14. PMID 35804978 DOI: 10.3390/cancers14133207 |
0.272 |
|
| 2011 |
Stevens KN, Vachon CM, Lee AM, Slager S, Lesnick T, Olswold C, Fasching PA, Miron P, Eccles D, Carpenter JE, Godwin AK, Ambrosone C, Winqvist R, Brauch H, ... ... Diasio RB, et al. Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Research. 71: 6240-9. PMID 21844186 DOI: 10.1158/0008-5472.Can-11-1266 |
0.272 |
|
| 2001 |
Heslin MJ, Li X, Johnson MR, Weiss H, Bland KI, Diasio RB, Urist MM. Co-expression of cyclooxygenase-2 (COX-2) and matrixmetalloproteinase (MMP)-2,-7 and-9 in human colorectal cancer Gastroenterology. 120: A342. DOI: 10.1016/S0016-5085(08)81703-9 |
0.272 |
|
| 1993 |
Zhang R, Liu T, Soong SJ, Diasio RB. A mathematical model of the kinetics and tissue distribution of 2-fluoro-beta-alanine, the major catabolite of 5-fluorouracil. Biochemical Pharmacology. 45: 2063-9. PMID 8512588 DOI: 10.1016/0006-2952(93)90017-Q |
0.271 |
|
| 1999 |
McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, Gonzalez FJ. Nomenclature for human DPYD alleles. Pharmacogenetics. 8: 455-9. PMID 9918128 DOI: 10.1097/00008571-199812000-00001 |
0.27 |
|
| 2006 |
Meropol NJ, Gold PJ, Diasio RB, Andria M, Dhami M, Godfrey T, Kovatich AJ, Lund KA, Mitchell E, Schwarting R. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4069-77. PMID 16943524 DOI: 10.1200/JCO.2005.05.2084 |
0.269 |
|
| 2012 |
Siddiq A, Couch FJ, Chen GK, Lindström S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomäki K, Amiano P, Apicella C, ... ... Diasio RB, et al. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Human Molecular Genetics. 21: 5373-84. PMID 22976474 DOI: 10.1093/Hmg/Dds381 |
0.269 |
|
| 2017 |
Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clinical Pharmacology and Therapeutics. PMID 29152729 DOI: 10.1002/Cpt.911 |
0.269 |
|
| 1997 |
Yan J, Lu Z, Walsh GM, Wheeler RH, Diasio RB. High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids. Journal of Chromatography. B, Biomedical Sciences and Applications. 690: 295-303. PMID 9106056 DOI: 10.1016/S0378-4347(96)00365-9 |
0.268 |
|
| 1996 |
Albin N, Johnson MR, Diasio RB. cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. Dna Sequence : the Journal of Dna Sequencing and Mapping. 6: 243-50. PMID 8912928 DOI: 10.3109/10425179609008450 |
0.267 |
|
| 1998 |
Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. British Journal of Clinical Pharmacology. 46: 1-4. PMID 9690942 DOI: 10.1046/J.1365-2125.1998.00050.X |
0.266 |
|
| 2014 |
Witzig TE, Hu G, Offer SM, Wellik LE, Han JJ, Stenson MJ, Dogan A, Diasio RB, Gupta M. Epigenetic mechanisms of protein tyrosine phosphatase 6 suppression in diffuse large B-cell lymphoma: Implications for epigenetic therapy Leukemia. 28: 147-154. PMID 23979523 DOI: 10.1038/Leu.2013.251 |
0.265 |
|
| 1989 |
Harris BE, Song RL, He YJ, Soong SJ, Diasio RB. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Biochemical Pharmacology. 37: 4759-62. PMID 3202908 DOI: 10.1016/0006-2952(88)90349-8 |
0.265 |
|
| 2013 |
Butterfield GL, Offer SM, Diasio RB. Abstract 2198: Possible circadian modulation of dihydropyrimidine dehydrogenase by mir-27a and mir-27b. Cancer Research. 73: 2198-2198. DOI: 10.1158/1538-7445.Am2013-2198 |
0.262 |
|
| 2011 |
Lee A, Nofziger C, Dossena S, Vanoni S, Diasio R, Paulmichl M. Methylation of the human pendrin promoter. Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology. 28: 397-406. PMID 22116354 DOI: 10.1159/000335102 |
0.256 |
|
| 2016 |
Offer SM, Diasio RB. Biomarkers of Fluorouracil Toxicity: Insight From the PETACC-8 Trial. Jama Oncology. PMID 26797288 DOI: 10.1001/Jamaoncol.2015.5463 |
0.253 |
|
| 2005 |
Boedefeld WM, Soong R, Weiss H, Diasio RB, Urist MM, Bland KI, Heslin MJ. E1A-F is overexpressed early in human colorectal neoplasia and associated with cyclooxygenase-2 and matrix metalloproteinase-7. Molecular Carcinogenesis. 43: 13-7. PMID 15800927 DOI: 10.1002/Mc.20093 |
0.251 |
|
| 2019 |
Dai J, Liu M, Yang Y, Li Q, Song N, Rocco G, Sihoe ADL, Gonzalez-Rivas D, Suen HC, He W, Duan L, Fan J, Zhao D, Wang H, Zhu Y, ... ... Diasio RB, et al. Optimal Lymph Nodes Examination and Adjuvant Chemotherapy for Stage I Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31009811 DOI: 10.1016/J.Jtho.2019.03.027 |
0.251 |
|
| 1991 |
Kwakye JB, Johnson MR, Barnes S, Grizzle WE, Diasio RB. Identification of bile acid-CoA: amino acid N-acyltransferase in rat kidney. The Biochemical Journal. 280: 821-4. PMID 1764044 DOI: 10.1042/Bj2800821 |
0.248 |
|
| 2004 |
Diasio RB. Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change? The New England Journal of Medicine. 350: 1777-9. PMID 15103005 DOI: 10.1056/Nejme048035 |
0.248 |
|
| 2014 |
Offer SM, Butterfield GL, Jerde CR, Fossum CC, Wegner NJ, Diasio RB. microRNAs miR-27a and miR-27b directly regulate liver dihydropyrimidine dehydrogenase expression through two conserved binding sites. Molecular Cancer Therapeutics. 13: 742-51. PMID 24401318 DOI: 10.1158/1535-7163.Mct-13-0878 |
0.247 |
|
| 2020 |
Schaerer D, Froehlich TK, Hamzic S, Offer SM, Diasio RB, Joerger M, Amstutz U, Largiadèr CR. A Novel Nomenclature for Repeat Motifs in the Thymidylate Synthase Enhancer Region and Its Relevance for Pharmacogenetic Studies. Journal of Personalized Medicine. 10. PMID 33086767 DOI: 10.3390/jpm10040181 |
0.246 |
|
| 1992 |
Kwakye JB, Johnson MR, Barnes S, Diasio RB. A comparative study of bile acid CoA:amino acid:N-acyltransferase (BAT) from four mammalian species. Comparative Biochemistry and Physiology. B, Comparative Biochemistry. 100: 131-6. PMID 1756615 DOI: 10.1016/0305-0491(91)90095-U |
0.245 |
|
| 1992 |
Zhang R, Barnes S, Diasio RB. Differential intestinal deconjugation of taurine and glycine bile acid N-acyl amidates in rats. The American Journal of Physiology. 262: G351-8. PMID 1539668 DOI: 10.1152/Ajpgi.1992.262.2.G351 |
0.241 |
|
| 1990 |
Johnson MR, Barnes S, Diasio RB. Radioassay of bile acid coenzyme A:glycine/taurine: N-acyltransferase using an n-butanol solvent extraction procedure. Analytical Biochemistry. 182: 360-5. PMID 2610352 DOI: 10.1016/0003-2697(89)90608-8 |
0.237 |
|
| 2002 |
Diasio RB. An evolving role for oral fluoropyrimidine drugs. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 894-6. PMID 11844808 DOI: 10.1200/Jco.2002.20.4.894 |
0.236 |
|
| 2013 |
Greenberg AJ, Lee AM, Serie DJ, McDonnell SK, Cerhan JR, Liebow M, Larson DR, Colby CL, Norman AD, Kyle RA, Kumar S, Rajkumar SV, Diasio RB, Slager SL, Vachon CM. Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma. Leukemia. 27: 515-6. PMID 22945773 DOI: 10.1038/Leu.2012.232 |
0.236 |
|
| 2014 |
Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, Berenberg JL, Goldberg RM, Diasio RB. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). Journal of the National Cancer Institute. 106. PMID 25381393 DOI: 10.1093/jnci/dju298 |
0.234 |
|
| 2011 |
Lewis M, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope F, Yoon HH. Association of body mass index (BMI) with smoking and prognosis in 721 patients with esophagogastric adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e14635. PMID 28021358 DOI: 10.1200/Jco.2011.29.15_Suppl.E14635 |
0.233 |
|
| 2012 |
Taga M, Mechanic LE, Hagiwara N, Vähäkangas KH, Bennett WP, Alavanja MC, Welsh JA, Khan MA, Lee A, Diasio R, Edell E, Bungum A, Jang JS, Yang P, Jen J, et al. EGFR somatic mutations in lung tumors: radon exposure and passive smoking in former- and never-smoking U.S. women. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 988-92. PMID 22523180 DOI: 10.1158/1055-9965.Epi-12-0166 |
0.233 |
|
| 2024 |
Zhang T, Ambrodji A, Huang H, Bouchonville KJ, Etheridge AS, Schmidt RE, Bembenek BM, Temesgen ZB, Wang Z, Innocenti F, Stroka D, Diasio RB, Largiadèr CR, Offer SM. Germline variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase (). Elife. 13. PMID 38686795 DOI: 10.7554/eLife.94075 |
0.231 |
|
| 2011 |
Yoon HH, Lewis MA, Shi Q, Khan M, Cassivi SD, Diasio RB, Sinicrope FA. Prognostic impact of body mass index stratified by smoking status in patients with esophageal adenocarcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4561-7. PMID 21990414 DOI: 10.1200/Jco.2011.37.1260 |
0.231 |
|
| 2016 |
Sprowl JA, Ong SS, Gibson AA, Hu S, Du G, Lin W, Li L, Bharill S, Ness RA, Stecula A, Offer SM, Diasio RB, Nies AT, Schwab M, Cavaletti G, et al. A phosphotyrosine switch regulates organic cation transporters. Nature Communications. 7: 10880. PMID 26979622 DOI: 10.1038/Ncomms10880 |
0.23 |
|
| 2023 |
Zhang T, Ambrodji A, Huang H, Bouchonville KJ, Etheridge AS, Schmidt RE, Bembenek BM, Temesgen ZB, Wang Z, Innocenti F, Stroka D, Diasio RB, Largiadèr CR, Offer SM. Germline variant determines epigenetic regulation of the anti-cancer drug metabolism gene dihydropyrimidine dehydrogenase ( ). Biorxiv : the Preprint Server For Biology. PMID 37961517 DOI: 10.1101/2023.11.01.565230 |
0.23 |
|
| 1991 |
Daher GC, Harris BE, Willard EM, Diasio RB. Biochemical basis for circadian-dependent metabolism of fluoropyrimidines. Annals of the New York Academy of Sciences. 618: 350-61. PMID 1826077 DOI: 10.1111/J.1749-6632.1991.Tb27255.X |
0.229 |
|
| 1991 |
Sweeny DJ, Barnes S, Diasio RB. Bile acid conjugation pattern in the isolated perfused rat liver during infusion of an amino acid formulation. Jpen. Journal of Parenteral and Enteral Nutrition. 15: 303-6. PMID 1907679 DOI: 10.1177/0148607191015003303 |
0.227 |
|
| 2017 |
Wu R, Nie Q, Tapper EE, Jerde CR, Offer SM, Diasio RB. Abstract 4069: Trimethylation and acetylation of Histone H3K27 modulates 5-fluorouracil response by regulating DPYD expression Cancer Research. 77: 4069-4069. DOI: 10.1158/1538-7445.Am2017-4069 |
0.226 |
|
| 1990 |
Sweeny DJ, Daher G, Barnes S, Diasio RB. Biological properties of the 2-fluoro-beta-alanine conjugates of cholic acid and chenodeoxycholic acid in the isolated perfused rat liver. Biochimica Et Biophysica Acta. 1054: 21-5. PMID 2116908 DOI: 10.1016/0167-4889(90)90200-W |
0.225 |
|
| 2012 |
Foote RL, Stafford SL, Petersen IA, Pulido JS, Clarke MJ, Schild SE, Garces YI, Olivier KR, Miller RC, Haddock MG, Yan E, Laack NN, Arndt CA, Buskirk SJ, Miller VL, ... ... Diasio RB, et al. The clinical case for proton beam therapy. Radiation Oncology (London, England). 7: 174. PMID 23083010 DOI: 10.1186/1748-717X-7-174 |
0.225 |
|
| 1996 |
Takimoto C, Lu Z, Zhang R, Diasio R, Liang M, Larson L, Cantilena L, Grem J, Allegra C, Chu E. Reversible 5-fluorouracil-associated encephalopathy in a dihydropyrimidine dehydrogenase (DPD) deficient patient. Clinical Pharmacology & Therapeutics. 59: 161-161. DOI: 10.1038/sj.clpt.1996.143 |
0.222 |
|
| 2016 |
Saif MW, Wasif K, Butler-Bowen H, Miller K, Diasio RB. Acquired factor VII deficiency following FOLFOX in a patient with colorectal cancer who was also DPD deficient Therapeutic Advances in Gastroenterology. 9: 121-127. DOI: 10.1177/1756283X15604115 |
0.221 |
|
| 1997 |
Diasio RB, Zhang R. Pharmacology of therapeutic oligonucleotides. Antisense & Nucleic Acid Drug Development. 7: 239-43. PMID 9212918 DOI: 10.1089/Oli.1.1997.7.239 |
0.22 |
|
| 2024 |
Le Teuff G, Cozic N, Boyer JC, Boige V, Diasio RB, Taieb J, Meulendijks D, Palles C, Schwab M, Deenen M, Largiadèr CR, Marinaki A, Jennings BA, Wettergren Y, Di Paolo A, et al. Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis. British Journal of Cancer. PMID 38225422 DOI: 10.1038/s41416-023-02517-2 |
0.215 |
|
| 2002 |
Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 768-74. PMID 11895907 |
0.214 |
|
| 2010 |
Khan M, Burch P, Wu T, Cassivi S, Diasio R, Yoon H. Prognostication of Long-Term Survival in Resected Esophageal Adenocarcinoma (EAC) American Journal of Gastroenterology. 105: S8. DOI: 10.14309/00000434-201010001-00020 |
0.214 |
|
| 1984 |
Sheidler VR, Ettinger DS, Diasio RB, Enterline JP, Brown MD. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine Journal of Clinical Pharmacology. 24: 155-159. PMID 6373843 DOI: 10.1002/j.1552-4604.1984.tb01824.x |
0.212 |
|
| 2007 |
Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? Jop : Journal of the Pancreas. 8: 799-805. PMID 17993734 |
0.212 |
|
| 1979 |
Diasio RB, Lakings DE, Bennett JE. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrobial Agents and Chemotherapy. 14: 903-8. PMID 742878 DOI: 10.1128/AAC.14.6.903 |
0.212 |
|
| 1997 |
Yan J, Tyring SK, McCrary MM, Lee PC, Haworth S, Raymond R, Olsen SJ, Diasio RB. The effect of sorivudine on dihydropyrimidine dehydrogenase activity in patients with acute herpes zoster. Clinical Pharmacology and Therapeutics. 61: 563-73. PMID 9164418 DOI: 10.1016/S0009-9236(97)90136-3 |
0.211 |
|
| 2001 |
Heslin MJ, Yan J, Johnson MR, Weiss H, Diasio RB, Urist MM. Role of matrix metalloproteinases in colorectal carcinogenesis. Annals of Surgery. 233: 786-92. PMID 11371737 DOI: 10.1097/00000658-200106000-00008 |
0.208 |
|
| 2011 |
Zhang R, Yan J, Shahinian H, Amin G, Lu Z, Liu T, Saag MS, Jiang Z, Temsamani J, Martin RR, Schechter PJ, Agrawal S, Diasio RB. Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3) Clinical Pharmacology & Therapeutics. 89. DOI: 10.1038/Clpt.2010.272 |
0.204 |
|
| 1985 |
Schuetz JD, Diasio RB. The effect of 5-fluorouracil on DNA chain elongation in intact bone marrow cells Biochemical and Biophysical Research Communications. 133: 361-367. PMID 4074377 DOI: 10.1016/0006-291X(85)91884-4 |
0.204 |
|
| 1981 |
Hall DJ, Diasio R, Goplerud DR. cis-Platinum in gynecologic cancer. III. Toxicity. American Journal of Obstetrics and Gynecology. 141: 309-12. PMID 7197123 DOI: 10.1016/S0002-9378(16)32638-2 |
0.202 |
|
| 1988 |
Schuetz JD, Wallace HJ, Diasio RB. DNA repair following incorporation of 5-fluorouracil into DNA of mouse bone marrow cells. Cancer Chemotherapy and Pharmacology. 21: 208-10. PMID 3359556 DOI: 10.1007/Bf00262771 |
0.201 |
|
| 2021 |
King DA, Diasio RB, Saif MW. Association of Pharmacogenetics With Adverse Events of Fluorouracil/Capecitabine in Patients With Cancer. Jco Oncology Practice. OP2001072. PMID 33793308 DOI: 10.1200/OP.20.01072 |
0.201 |
|
| 1999 |
Diasio RB. Dihydropyrimidine dehydrogenase and resistance to 5-fluorouracil. Progress in Experimental Tumor Research. 36: 115-23. PMID 10386069 DOI: 10.1159/000061992 |
0.196 |
|
| 1978 |
Breiter DN, Diasio RB, Neifeld JP, Roush ML, Rosenberg SA. Serum copper and zinc measurement in patients with osteogenic sarcoma. Cancer. 42: 598-602. PMID 307981 DOI: 10.1002/1097-0142(197808)42:2<598::AID-CNCR2820420228>3.0.CO;2-P |
0.194 |
|
| 1998 |
Schilsky RL, Hohneker J, Ratain MJ, Janisch L, Smetzer L, Lucas VS, Khor SP, Diasio R, Von Hoff DD, Burris HA. Phase I clinical and pharmacologic study of Eniluracil plus fluorouracil in patients with advanced cancer Journal of Clinical Oncology. 16: 1450-1457. PMID 9552051 DOI: 10.1200/JCO.1998.16.4.1450 |
0.193 |
|
| 2021 |
Diasio RB, Innocenti F, Offer SM. Pharmacogenomic-Guided Therapy in Colorectal Cancer. Clinical Pharmacology and Therapeutics. PMID 34114648 DOI: 10.1002/cpt.2334 |
0.19 |
|
| 2021 |
Hamzic S, Schärer D, Offer S, Meulendijks D, Nakas C, Diasio R, Fontana S, Wehrli M, Schürch S, Amstutz U, Largiadèr CR. Haplotype structure defines effects of common DPYD variants c.85T>C (rs1801265) and c.496A>G (rs2297595) on DPD activity: implication for 5-fluorouracil toxicity. British Journal of Clinical Pharmacology. PMID 33491253 DOI: 10.1111/bcp.14742 |
0.181 |
|
| 1994 |
Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 2239-42. PMID 7964937 DOI: 10.1200/JCO.1994.12.11.2239 |
0.177 |
|
| 1981 |
Diasio RB, Ettinger DS, Satterwhite BE. Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations Journal of Clinical Pharmacology. 21. PMID 7298876 DOI: 10.1002/j.1552-4604.1981.tb02579.x |
0.176 |
|
| 1976 |
Myers CE, Diasio R, Eliot HM, Chabner BA. Pharmacokinetics of the fluoropyrimidines: implications for their clinical use Cancer Treatment Reviews. 3: 175-183. PMID 963687 DOI: 10.1016/S0305-7372(76)80021-7 |
0.176 |
|
| 1986 |
Harris BE, Manning BW, Federle TW, Diasio RB. Conversion of 5-fluorocytosine to 5-fluorouracil by human intestinal microflora. Antimicrobial Agents and Chemotherapy. 29: 44-8. PMID 3729334 DOI: 10.1128/AAC.29.1.44 |
0.171 |
|
| 2016 |
Diasio RB. Current insights into the impact of dihydropyrimidine dehydrogenase deficiency in patients receiving treatment with 5-fluorouracil. Clinical Advances in Hematology & Oncology : H&O. 14: 510-2. PMID 27379945 |
0.168 |
|
| 2006 |
Ezzeldin HH, Diasio RB. Genetic testing in cancer therapeutics. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 4137-41. PMID 16857783 DOI: 10.1158/1078-0432.CCR-06-0707 |
0.168 |
|
| 1983 |
Kerkering TM, Schwartz PM, Espinel-Ingroff A, Turek PJ, Diasio RB. 5-fluorocytosine susceptibility of pathogenic fungi in the presence of allopurinol: potential for improving the therapeutic index of 5-fluorocytosine. Antimicrobial Agents and Chemotherapy. 24: 448-9. PMID 6639003 DOI: 10.1128/AAC.24.3.448 |
0.159 |
|
| 2004 |
Diasio RB. Selecting regimens in advanced colon cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 2: S-19-24. PMID 23570094 |
0.156 |
|
| 2008 |
Diasio RB. Overview of Cancer Pharmacogenomics Aacr Education Book. 2008: 461-464. DOI: 10.1158/AACR.EDB-08-8069 |
0.156 |
|
| 2000 |
Baker SD, Diasio RB, O'Reilly S, Lucas VS, Khor SP, Sartorius SE, Donehower RC, Grochow LB, Spector T, Hohneker JA, Rowinsky EK. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil Journal of Clinical Oncology. 18: 915-926. PMID 10673535 DOI: 10.1200/JCO.2000.18.4.915 |
0.156 |
|
| 2023 |
Lumish M, Thackray J, Do RKG, Caudle KE, Amstutz U, Schwab M, Diasio RB, Jarnagin WR, Cercek A. Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine. Jco Precision Oncology. 7: e2200442. PMID 36848609 DOI: 10.1200/PO.22.00442 |
0.151 |
|
| 2004 |
Saif MW, Eloubeidi M, Thornton J, Johns J, Diasio R, Johnson MR, Moisa CF, Russo S. Up-regulation of thymidine phosphorylase (TP) by radiotherapy (RT): a phase I study of capecitabine (CAP) with concurrent RT for pts with locally advanced (LA) pancreatic cancer (Pan Ca) Journal of Clinical Oncology. 22: 4104-4104. DOI: 10.1200/JCO.2004.22.90140.4104 |
0.143 |
|
| 2003 |
Salesiotis A, Soong R, Diasio RB, Frost A, Cullen KJ. Capecitabine induces rapid, sustained response in two patients with extensive oral verrucous carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 580-5. PMID 12576421 |
0.142 |
|
| 2005 |
Gross E, Seck K, Riemer S, Kates R, Ullrich T, Lutz V, Harbeck N, Schmitt M, Diasio R, Kiechle M. Genotyping of Caucasian individuals in the dihydropyrimidine dehydrogenase gene Zentralblatt FüR GynäKologie. 127. DOI: 10.1055/s-2005-921001 |
0.139 |
|
| 1981 |
Hall DJ, Diasio R, Goplerud DR. cis-Platinum in gynecologic cancer. I. Epithelial ovarian cancer. American Journal of Obstetrics and Gynecology. 141: 299-304. PMID 7197121 DOI: 10.1016/S0002-9378(16)32636-9 |
0.139 |
|
| 1987 |
Sweeny DJ, Barnes S, Heggie GD, Diasio RB. Metabolism of 5-fluorouracil to an N-cholyl-2-fluoro-beta-alanine conjugate: previously unrecognized role for bile acids in drug conjugation. Proceedings of the National Academy of Sciences of the United States of America. 84: 5439-43. PMID 3110788 DOI: 10.1073/pnas.84.15.5439 |
0.136 |
|
| 2006 |
Diasio R. 4–35 CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer Treatment Breast Diseases: a Year Book Quarterly. 16: 372-374. DOI: 10.1016/S1043-321X(05)80305-4 |
0.128 |
|
| 2023 |
Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, et al. Testing: Time to Put Patient Safety First. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202364. PMID 36821823 DOI: 10.1200/JCO.22.02364 |
0.126 |
|
| 2020 |
Saif MW, Hachem H, Purvey S, Hamal R, Zhang L, Siddiqui NS, Godara A, Diasio RB. Pharmacogenetic Variants in the and Genes are Clinically Significant Predictors of Fluoropyrimidine Toxicity: Are We Ready for Use in our Clinical Practice. Archives of Pharmacology and Therapeutics. 2: 6-8. PMID 33283204 |
0.124 |
|
| 1993 |
Zhang R, Lu Z, Liu T, Soong SJ, Diasio RB. Circadian rhythm of rat spleen cytoplasmic thymidine kinase. Biochemical Pharmacology. 45: 1115-9. PMID 8461041 DOI: 10.1016/0006-2952(93)90256-V |
0.122 |
|
| 1979 |
Diasio RB, Eanes RZ, Chen ML, Madge GE, Mellette SJ. Adenocarcinoma of the pancreas associated with hypoglycemia: case report and review of the literature. Cancer. 43: 2457-64. PMID 378358 DOI: 10.1002/1097-0142(197906)43:6<2457::AID-CNCR2820430642>3.0.CO;2-4 |
0.118 |
|
| 2020 |
Ly RC, Schmidt RE, Kiel PJ, Pratt VM, Schneider BP, Radovich M, Offer SM, Diasio RB, Skaar TC. Severe Capecitabine Toxicity Associated With a Rare Variant Identified Through Whole-Genome Sequencing. Jco Precision Oncology. 4. PMID 32923881 DOI: 10.1200/PO.20.00067 |
0.116 |
|
| 1997 |
Diasio RB, Johnson MR, Albin N. Mutations at codon 974 of the DPYD gene are a rare event. British Journal of Cancer. 76: 1113. PMID 9376276 DOI: 10.1038/bjc.1997.518 |
0.111 |
|
| 1998 |
Diasio RB. A Clinician's Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics Mayo Clinic Proceedings. 73: 809. DOI: 10.4065/73.8.809 |
0.109 |
|
| 1982 |
Armstrong RD, Diasio RB. Improved measurement of thymidylate synthetase activity by a modified tritium-release assay. Journal of Biochemical and Biophysical Methods. 6: 141-7. PMID 7108126 DOI: 10.1016/0165-022X(82)90060-4 |
0.108 |
|
| 2004 |
Lee A, Ezzeldin H, Fourie J, Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clinical Advances in Hematology & Oncology : H&O. 2: 527-32. PMID 16163233 |
0.107 |
|
| 1981 |
Hall DJ, Diasio R, Goplerud DR. cis-Platinum in gynecologic cancer. II. Squamous cell carcinoma of the cervix. American Journal of Obstetrics and Gynecology. 141: 305-8. PMID 7197122 DOI: 10.1016/S0002-9378(16)32637-0 |
0.098 |
|
| 1984 |
Mentre F, Steimer JL, Sommadossi JP, Diasio RB, Cano JP. A mathematical model of the kinetics of 5-fluorouracil and its catabolites in freshly isolated rat hepatocytes. Biochemical Pharmacology. 33: 2727-32. PMID 6431993 DOI: 10.1016/0006-2952(84)90688-9 |
0.097 |
|
| 2018 |
Shrestha S, Tapper EE, Trogstad-Isaacson CS, Hobday TJ, Offer SM, Diasio RB. Dose modification for safe treatment of a compound complex heterozygous variant carrier with 5-fluorouracil. Jco Precision Oncology. 2. PMID 32039342 DOI: 10.1200/po.18.00179 |
0.096 |
|
| 1996 |
Diasio RB, Lu Z, Zhang R, Shahinian HS. Fluoropyrimidine catabolism. Cancer Treatment and Research. 78: 71-93. PMID 8595148 DOI: 10.1007/978-1-4615-2007-8_4 |
0.094 |
|
| 1991 |
Stagg MP, Diasio RB. Novel chemotherapeutic agents in early clinical development. Current Opinion in Oncology. 2: 1119-25. PMID 1983089 DOI: 10.1097/00001622-199012000-00016 |
0.087 |
|
| 2006 |
Yu J, McLeod HL, Ezzeldin HH, Diasio RB. Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 3864; author reply 3. PMID 16778115 DOI: 10.1158/1078-0432.CCR-06-0549 |
0.085 |
|
| 2005 |
Robert F, Robert S, deShazo M, Reddy V, Diasio R, Ezzeldin H, Carey D, Chen D, Schreeder M, Ross D. PD-021 Tissue microarray for protein profiling in non-small cell lungcancer (NSCLC): Discovery and validation of novel biomarkers for prediction of recurrence and treatment response Lung Cancer. 49: S72-S73. DOI: 10.1016/S0169-5002(05)80354-X |
0.085 |
|
| 1986 |
Diasio RB, Wilburn ME, Shadomy S, Espinel-Ingroff A. Rapid determination of serum 5-fluorocytosine levels by high-performance liquid chromatography. Antimicrobial Agents and Chemotherapy. 13: 500-4. PMID 263889 DOI: 10.1128/AAC.13.3.500 |
0.085 |
|
| 2021 |
ReFaey K, Tripathi S, Grewal SS, Bhargav AG, Quinones DJ, Chaichana KL, Antwi SO, Cooper LT, Meyer FB, Dronca RS, Diasio RB, Quinones-Hinojosa A. Cancer Mortality Rates Increasing vs Cardiovascular Disease Mortality Decreasing in the World: Future Implications. Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 5: 645-653. PMID 34195556 DOI: 10.1016/j.mayocpiqo.2021.05.005 |
0.084 |
|
| 1993 |
Boulieu R, Lenoir A, Mornex JF, Bohman C, Balzarini J, Wigerinck P, Aerschot A, Herdewijn P, Clercq E, Brosh S, Zoref-Shani E, Sperling O, Danziger E, Sidi Y, Bromberg Y, ... ... Diasio RB, et al. Abstracts of oral presentations Pharmacy World & Science. 15: F7-F14. DOI: 10.1007/BF02297670 |
0.075 |
|
| 2003 |
Diasio R. Alternative schedules with irinotecan. Seminars in Oncology. 30: 18-24. PMID 14508723 DOI: 10.1016/S0093-7754(03)00330-0 |
0.056 |
|
| 1979 |
Diasio RB, Wilburn ME. Effect of Subambient Column Temperature on Resolution of Flouorouracil Metabolites in Reversed-Phase High Performance Liquid Chromatography Journal of Chromatographic Science. 17: 565-567. DOI: 10.1093/chromsci/17.10.565 |
0.037 |
|
| 1996 |
KERR A, DIASIO RB, BOMMER WJ. EFFECT OF ALTITUDE (HYPOXIA) ON CORONARY ARTERY SIZE IN THE WHITE RAT. American Heart Journal. 69: 841. PMID 14296650 DOI: 10.1016/0002-8703(65)90460-6 |
0.023 |
|
| 2008 |
Saif MW, Tomita M, Ledbetter L, Diasio RB. Capecitabine-related cardiotoxicity: recognition and management. The Journal of Supportive Oncology. 6: 41-8. PMID 18257400 |
0.022 |
|
| 1971 |
Diasio RB, Glass RH. Effects of pH on the migration of X and Y sperm. Fertility and Sterility. 22: 303-5. PMID 4102480 DOI: 10.1016/S0015-0282(16)38224-3 |
0.01 |
|
| 1971 |
Diasio RB, Glass RH. The Y chromosome in sperm of an XYY male. Lancet (London, England). 2: 1318-9. PMID 4098814 DOI: 10.1016/S0140-6736(70)92286-5 |
0.01 |
|
| Hide low-probability matches. |